{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ferrari-Souza JP"],"funding":["Ministry of Science, Technology and Innovation | Conselho Nacional de Desenvolvimento Científico e Tecnológico (National Council for Scientific and Technological Development)","European Research Council","NIA NIH HHS","Fondation Brain Canada (Fondation Neuro Canada)","Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Brazilian Federal Agency for the Support and Evaluation of Graduate Education)","Fonds de Recherche du Québec - Santé (Fonds de la recherche en sante du Quebec)","U.S. Department of Health & Human Services | National Institutes of Health (NIH)","Alzheimer's Association","Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada)"],"pagination":["4781-4789"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9734046"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["27(11)"],"pubmed_abstract":["Astrocytes can adopt multiple molecular phenotypes in the brain of Alzheimer's disease (AD) patients. Here, we studied the associations of cerebrospinal fluid (CSF) glial fibrillary acidic protein (GFAP) and chitinase-3-like protein 1 (YKL-40) levels with brain amyloid-β (Aβ) and tau pathologies. We assessed 121 individuals across the aging and AD clinical spectrum with positron emission tomography (PET) brain imaging for Aβ ([<sup>18</sup>F]AZD4694) and tau ([<sup>18</sup>F]MK-6240), as well as CSF GFAP and YKL-40 measures. We observed that higher CSF GFAP levels were associated with elevated Aβ-PET but not tau-PET load. By contrast, higher CSF YKL-40 levels were associated with elevated tau-PET but not Aβ-PET burden. Structural equation modeling revealed that CSF GFAP and YKL-40 mediate "],"journal":["Molecular psychiatry"],"pubmed_title":["Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer's disease."],"pmcid":["PMC9734046"],"funding_grant_id":["R01 AG073267","NIRP-12-259245","2020-VICO-279314","AACSF-20-648075","435642/2018-9","NIRG-12-92090","R01AG073267","R01AG075336","R01 AG075336","MOP-11-51-31","720931","33397","681712","88887.627297/2021-00","312410/2018- 2"],"pubmed_authors":["Kang MS","Klunk WE","Gauthier S","Ferrari-Souza JP","Zimmer ER","Villemagne VL","Stevenson J","Rocha A","Zetterberg H","Leffa DT","De Bastiani MA","Chamoun M","Pascoal TA","Benedet AL","Poltronetti NM","Therriault J","Rahmouni N","Cohen AD","Servaes S","Ferreira PCL","Bellaver B","Rosa-Neto P","Tissot C","Tudorascu DL","Souza DO","Ashton NJ","Brum WS","Bezgin G","Pallen V","Wang YT","Karikari TK","Blennow K","Lussier FZ"],"additional_accession":[]},"is_claimable":false,"name":"Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer's disease.","description":"Astrocytes can adopt multiple molecular phenotypes in the brain of Alzheimer's disease (AD) patients. Here, we studied the associations of cerebrospinal fluid (CSF) glial fibrillary acidic protein (GFAP) and chitinase-3-like protein 1 (YKL-40) levels with brain amyloid-β (Aβ) and tau pathologies. We assessed 121 individuals across the aging and AD clinical spectrum with positron emission tomography (PET) brain imaging for Aβ ([<sup>18</sup>F]AZD4694) and tau ([<sup>18</sup>F]MK-6240), as well as CSF GFAP and YKL-40 measures. We observed that higher CSF GFAP levels were associated with elevated Aβ-PET but not tau-PET load. By contrast, higher CSF YKL-40 levels were associated with elevated tau-PET but not Aβ-PET burden. Structural equation modeling revealed that CSF GFAP and YKL-40 mediate ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2026-04-12T15:07:54.106Z","creation":"2025-04-05T21:25:41.624Z"},"accession":"S-EPMC9734046","cross_references":{"pubmed":["35948658"],"doi":["10.1038/s41380-022-01716-2"]}}